Program
elinzanetant
Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.
Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 212 open or running | phase 3since Aug 26, 2021 | Aug 3, 2016 | Jan 22, 2027phase 1 · NCT07762287 |
| GlaxoSmithKline | 30 open or running | phase 1since Mar 4, 2010 | Mar 4, 2010 | none ahead |
Also a collaborator on its studies: nerre-therapeutics-ltd and quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Mar 4, 2010.
- Nov 25, 2020Phase 1 study in HealthyBayer · NCT04654897 · 6 enrolled · United Kingdom
- Apr 7, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04845841 · 16 enrolled · Germany
- May 14, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT04889287, NCT04903821
- Jul 5, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04981431 · 62 enrolled · Japan
- Aug 26, 20212 phase 3 studies in Hot FlashesBayer · NCT05042362, NCT05030584
- Aug 26, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05028608 · 16 enrolled · Germany
- Sep 20, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05061563, NCT05071729
- Oct 19, 2021Phase 3 study in Hot FlashesBayer · NCT05099159 · 400 enrolled · United States, Canada, Czechia and more
- Apr 25, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05351892, NCT05381142
- Jul 21, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05471817, NCT05481528
- Oct 17, 2022Phase 3 study in Hot FlashesBayer · NCT05587296 · 474 enrolled · Austria, Belgium, Canada and more
- Oct 27, 2023Phase 2 study in Sleep Disturbances Associated With MenopauseBayer · NCT06112756 · 110 enrolled · United States, Austria, Belgium and more
- Dec 21, 2023Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT06219902 · 64 enrolled · Canada
- Jul 15, 2026Phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287 · 100 planned · Canada
Ahead
- Jan 22, 2027Primary completion: phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287
TargetBeta
“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07762287Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women · Canada | 1 | Recruiting | Bayer | Jan 22, 2027 | 100 |
| NCT06219902Multiple Endocrine Neoplasia Type 1 · Canada | 1 | Completed | Bayer | Apr 15, 2024 | 64 |
| NCT06112756Sleep Disturbances Associated With Menopause · United States, Austria, Belgium and more | 2 | Completed | Bayer | Aug 22, 2024 | 110 |
| NCT05587296Hot Flashes · Austria, Belgium, Canada and more | 3 | Active, not recruiting | Bayer | Jan 29, 2024 | 474 |
| NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Feb 7, 2023 | 51 |
| NCT05471817Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Sep 20, 2022 | 20 |
| NCT05381142Multiple Endocrine Neoplasia Type 1 · China | 1 | Completed | Bayer | Jul 11, 2022 | 16 |
| NCT05351892Multiple Endocrine Neoplasia Type 1 · United States | 1 | Completed | Bayer | Jun 9, 2022 | 18 |
| NCT05099159Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Bayer | Jun 13, 2023 | 400 |
| NCT05071729Multiple Endocrine Neoplasia Type 1 · United States | 1 | Completed | Bayer | Oct 19, 2022 | 31 |
| NCT05061563Multiple Endocrine Neoplasia Type 1 · Netherlands | 1 | Completed | Bayer | Dec 9, 2021 | 14 |
| NCT05030584Hot Flashes · United States, Belgium, Bulgaria and more | 3 | Completed | Bayer | Mar 29, 2023 | 628 |
| NCT05042362Hot Flashes · United States, Austria, Czechia and more | 3 | Completed | Bayer | Jul 25, 2023 | 396 |
| NCT05028608Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Oct 31, 2021 | 16 |
| NCT04981431Multiple Endocrine Neoplasia Type 1 · Japan | 1 | Completed | Bayer | Mar 13, 2022 | 62 |
| NCT04903821Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Mar 15, 2022 | 33 |
| NCT04889287Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Jul 23, 2021 | 16 |
| NCT04845841Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Jun 1, 2021 | 16 |
| NCT04654897Healthy · United Kingdom | 1 | Completed | Bayer | Oct 29, 2020 | 6 |
| NCT03596762Hot Flashes · United States, Canada, United Kingdom | 2 | Completed | Bayer | Nov 21, 2019 | 199 |
| NCT02865538Hot Flashes · United States | 2 | Completed | Bayer | Mar 28, 2017 | 76 |
| NCT01381419Schizophrenia · United Kingdom | 1 | Completed | GlaxoSmithKline | Apr 1, 2009 | 21 |
| NCT01209039Schizophrenia · United Kingdom | 1 | Completed | GlaxoSmithKline | Oct 25, 2009 | 41 |
| NCT01090440Schizophrenia · Australia | 1 | Completed | GlaxoSmithKline | Oct 9, 2009 | 16 |
How it is read
Names in the registry
- “Elinzanetant (BAY3427080)”, 15 entries
- “GSK1144814”, 7 entries
- “BAY3427080”, 2 entries
- “Elinzanetant (BAY 3427080) treatment A”, 1 entry
- “Elinzanetant (BAY 3427080) treatment B”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 13 studies
- Schizophrenia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.